Friday, July 25, 2014
Gilead Sciences Inc., of Foster City, Calif., saw shares (NASDAQ:GILD) trading flat Thursday despite Wednesday's post-close report that sales of the company's hepatitis C treatment Sovaldi (sofosbuvir) hit nearly $3.5 billion for the second quarter, swelling its net profit to about $3.66 billion, or $2.20 per share, up from $772.6 million, or 46 cents per share, a year ago.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.